Response to Kellner and Fink.
From the MoodNet Research Group and Division of Psychiatry, Stavanger University Hospital, Stavanger, Norway; the MoodNet Research Group and Division of Psychiatry, Haukeland University Hospital, Bergen, Norway; Faculty of Medicine and Dentistry, Clinical Institute, University of Bergen, Norway; NORMENT, KB Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Norway; Research Department, Stavanger University Hospital and Faculty of Science and Technology, University of Stavanger, Norway; the Østmarka Department of Psychiatry, St. Olav University Hospital of Trondheim and Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Helle K
HK
Schoeyen
Ute
U
Kessler
Ole A
OA
Andreassen
Bjoern H
BH
Auestad
Per
P
Bergsholm
Ulrik F
UF
Malt
Gunnar
G
Morken
Ketil J
KJ
Oedegaard
Arne
A
Vaaler
D000928:Antidepressive Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000628:therapy*; D061218:Depressive Disorder, Treatment-Resistant / Q000628:therapy*; D004565:Electroconvulsive Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male
D000928:Antidepressive Agents